Facebook X (Twitter) Instagram
    Facebook Instagram Threads
    Global BiodefenseGlobal Biodefense
    Subscribe
    • Featured News
    • Funding
    • Directory
    • Jobs
    • Events
    Global BiodefenseGlobal Biodefense
    CBRNE

    RFP – Nuclear Medical Countermeasure Development

    By Global Biodefense StaffAugust 26, 2014
    Biodefense Vaccine Development
    Credit: Shutterstock, modified by Global Biodefense
    Share
    Facebook LinkedIn Reddit Email

    The National Institute of Allergy and Infectious Diseases (NIAID) Division of Allergy, Immunology and Transplantation (DAIT) has a requirement for developing products for treatment of radiation injuries from exposures due to a nuclear and radiological attacks.

    NIAID is soliciting proposals for a contract entitled “Radiation/Nuclear Medical Countermeasure Product Development Support Services” to advance the development of candidate medical countermeasures (MCMs).

    Research and development studies supported by this RFP will advance candidate MCMs to a stage where products are eligible for advanced product development by the Biomedical Advanced Research and Development Authority (BARDA) or acquisition under the Project BioShield Act of 2004.

    It is anticipated that one Indefinite Delivery Indefinite Quantity type contract will be awarded for a 5-year period of performance beginning on or about August 1, 2015.

    The Task Areas will include:

    • Administrative and Technical Support
    • Animal Model Development and Efficacy Testing of Candidate Medical Countermeasures
    • Nonclinical Studies in Support of IND/NDA/BLA
    • Phase I Clinical Studies
    • Chemistry, Manufacturing and Control Support Services

    The first Task Area is anticipated to encompass a cost-reimbursement, term (level of effort) Task Order and the others completion type cost reimbursement Task Orders.  Options may be used to extend the period of performance of some Task Orders.

    Further details are available under Solicitation Number: RFP-NIAID-DAIT-NIHAI2014005. The response deadline is December 1, 2014.

    Animal Models ASPR BARDA HHS NIAID Radiation
    Share. Facebook LinkedIn Reddit Email
    Previous ArticleLLNL Seeks Partner for Fast PCR Instrument
    Next Article Ebola Planning vs. Ebola Risk

    Related Stories

    Jurata Thin Film and CastleVax Awarded Grant to Advance Thermostabilized COVID-19 Booster

    September 20, 2023

    SOREX Brings Top CBRNE Units to Dugway Proving Ground

    September 20, 2023

    Biomarkers for Detection of Exposure to Nitrogen Mustards

    September 20, 2023

    Mount Sinai to Lead Development of Pan-Coronavirus Vaccine Under New Federal Grant

    September 17, 2023
    News Scan

    Biodefense Headlines – 19 September 2023

    News Scan September 19, 2023

    News highlights on health security threats and countermeasures curated by Global Biodefense This week’s selections include a global survey of gain-of-function research; funding of an mRNA mpox vaccine; Nipah virus outbreak in India; field detection of threat agents with acoustic…

    Upcoming Events

    Oct 3
    Virtual Event Virtual Event
    October 3 - October 5

    OneLab Summit 2023

    Oct 3
    Virtual Event Virtual Event
    12:00 pm - 2:00 pm EDT

    Public-Private Partnerships to Distribute, Dispense, and Administer Medical Countermeasures

    Oct 4
    Virtual Event Virtual Event
    10:00 am - 2:00 pm EDT

    Tunneling Nanotubes and Intracellular Protrusions Workshop

    Oct 12
    Virtual Event Virtual Event
    12:00 pm - 2:00 pm EDT

    Public-Private Partnerships for Acceptance and Uptake of Medical Countermeasures

    View Calendar

    Subscribe to Global Biodefense

    Get the latest news on pathogens and preparedness

    © 2023 Stemar Media Group LLC
    • About
    • Contact
    • Privacy
    • Subscribe

    Type above and press Enter to search. Press Esc to cancel.